Boston Scientific Corporation (BIT:1BSX)
Italy · Delayed Price · Currency is EUR | Market Cap | 64.48B -52.3% |
| Revenue (ttm) | 17.88B +17.4% |
| Net Income | 3.09B +75.4% |
| EPS | 2.07 +74.4% |
| Shares Out | n/a |
| PE Ratio | 20.85 |
| Forward PE | 14.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 43.62 |
| Previous Close | 44.71 |
| Day's Range | 43.28 - 43.79 |
| 52-Week Range | 43.28 - 94.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Boston Scientific price target lowered to $70 from $87 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $70 from $87 and keeps a Buy rating on the shares. The firm cites the company’s…
Boston Scientific price target lowered to $70 from $75 at Baird
Baird lowered the firm’s price target on Boston Scientific (BSX) to $70 from $75 and keeps an Outperform rating on the shares. The firm updated its model and lowered estimates…
Boston Scientific price target lowered to $74 from $87 at Leerink
Leerink lowered the firm’s price target on Boston Scientific (BSX) to $74 from $87 and keeps an Outperform rating on the shares.
Boston Scientific price target lowered to $89 from $96 at Barclays
Barclays lowered the firm’s price target on Boston Scientific (BSX) to $89 from $96 and keeps an Overweight rating on the shares. The firm says the company yesterday set appropriate…
Boston Scientific downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Larry Biegelsen downgraded Boston Scientific (BSX) to Equal Weight from Overweight with a price target of $55, down from $75. The firm sees near-term uncertainty for the…
Boston Scientific price target lowered to $75 from $85 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Boston Scientific (BSX) to $75 from $85 and keeps a Buy rating on the shares. Boston Scientific lowered expectations for…
Boston Scientific slides after flagging slowdown in Watchmen heart device usage
Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device maker flagged declining usage of its heart disease device.
Here’s Why Boston Scientific Stock (BSX) Is Crashing Today
Management provided a corporate update.
Boston Scientific Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Organic growth guidance was revised down due to headwinds in WATCHMAN, EP, and urology, but confidence remains in margin and EPS targets. Key growth drivers include new launches in EP, interventional cardiology, and the Penumbra and MiRus deals. Long-term growth is anchored in innovation and portfolio expansion.
Belo Sun Announces 2026 Shareholder Meeting Voting Results and Corporate Update
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election...
Belo Sun Provides Update on Ongoing Proceedings Before TRF-1
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th ...
Boston Scientific reports FRACTURE trial meets primary endpoint
Boston Scientific (BSX) announced results from the FRACTURE Investigational Device Exemption trial evaluating the use of the Seismiq 4CE Coronary Intravascular Lithotripsy Catheter to treat patients w...
Boston Scientific price target lowered to $75 from $78 at Baird
Baird lowered the firm’s price target on Boston Scientific (BSX) to $75 from $78 and keeps an Outperform rating on the shares. The firm updated its model following its re-entry…
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. ...
3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
Three names are expected to have strong setups this week: Zeta Global ($ZETA), Boston Scientific ($BSX), and Summit Therapeutics ($SMMT). Each stock has its own catalyst, and analysts see room…
Here’s Why Boston Scientific’s Stock (BSX) Is Surging Today
The medical device maker is undertaking a big acquisition.
Boston Scientific price target lowered to $68 from $105 at BofA
BofA lowered the firm’s price target on Boston Scientific (BSX) to $68 from $105 and keeps a Buy rating on the shares. After having hosted 34 medtech companies last week…
Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held MiRus LLC in return for a 34% equity stake and potential access to the startup's heart-valve...
Boston Scientific enters $2B accelerated share repurchase agreement
Boston Scientific (BSX) announced that it has entered into an accelerated share repurchase agreement with JPMorgan Chase Bank, National Association for $2B of its common stock, as part of its…
Boston Scientific enters into $2 billion accelerated share repurchase agreement
MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase ...
Boston Scientific Slides: Acquisition presentation
Boston Scientific has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Boston Scientific invests $1.5B for 34% equity stake in MiRus
Boston Scientific (BSX) announced it has invested $1.5B in return for an approximately 34% equity stake in MiRus, a privately-held company developing and commercializing proprietary biomaterials, impl...
Boston Scientific announces strategic investment in MiRus LLC
Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientif...
Belo Sun to Commence Technical Studies on Volta Grande Gold Project
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Go...
Boston Scientific issues correction for ACCOLADE pacemakers, FDA says
The FDA is aware that Boston Scientific (BSX) has issued a letter to affected customers recommending all ACCOLADE pacemakers and CRT-Ps be corrected prior to continued use, the agency announced.